IBIO
iBio, Inc. NASDAQ Listed Aug 19, 2008$1.19
-0.83%
vs $1.20
Mkt Cap $18.8M
52w Low $0.78
13.5% of range
52w High $3.82
50d MA $1.36
200d MA $1.85
P/E (TTM)
—
EV/EBITDA
—
P/B
0.8x
Debt/Equity
0.2x
ROE
-40.7%
P/FCF
-0.8x
RSI (14)
39.10
ATR (14)
$0.06
Beta
1.36
50d MA
$1.36
200d MA
$1.85
Avg Volume
736.6K
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.
8800 HSC Parkway · Bryan, TX 77807 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 28, 2026 | TNS | -0.07 | -0.04 | +42.9% | 1.36 | +0.0% | -6.6% | -0.8% | +4.0% | -0.8% | +0.8% | — |
| May 12, 2026 | TNS | -0.06 | -0.07 | -16.7% | 1.61 | +0.6% | -3.7% | +0.6% | -5.8% | -3.4% | +5.6% | — |
| Feb 10, 2026 | TNS | -0.08 | -0.09 | -12.5% | 2.27 | +2.2% | -2.6% | -4.5% | +5.2% | +3.2% | +1.7% | — |
| Nov 12, 2025 | TNS | -0.07 | -0.11 | -57.1% | 1.25 | -0.8% | -8.0% | +0.9% | -5.2% | +10.0% | -9.9% | — |
| Sep 5, 2025 | TNS | -0.39 | -0.31 | +20.5% | 0.83 | -0.8% | +2.4% | -2.6% | +6.0% | +9.1% | -3.1% | — |
| May 2, 2025 | TNS | -0.39 | -0.49 | -25.6% | 1.01 | +7.9% | -3.0% | -13.3% | +0.0% | -2.4% | -7.2% | — |
| Feb 10, 2025 | TNS | -0.45 | -0.48 | -6.7% | 3.42 | -5.0% | -7.3% | +16.1% | -2.2% | -4.7% | +7.3% | — |
| Nov 12, 2024 | TNS | -0.48 | -0.46 | +4.2% | 2.55 | +0.0% | -9.0% | -7.3% | +6.0% | -4.4% | +2.3% | — |
| Sep 25, 2024 | TNS | -0.47 | -0.91 | -93.6% | 1.82 | +3.8% | +7.1% | +6.7% | +6.7% | +4.5% | -3.9% | — |
| May 14, 2024 | TNS | — | -0.71 | — | 1.88 | +1.6% | +0.0% | -3.7% | +9.4% | +8.6% | +8.4% | — |
| May 13, 2024 | AMC | — | -0.71 | — | 1.82 | -0.5% | +3.3% | +0.0% | -3.7% | +9.4% | +8.6% | — |
| Feb 9, 2024 | TNS | -8.20 | -2.42 | +70.5% | 1.18 | -1.7% | +2.5% | +0.8% | -0.8% | +0.8% | +3.3% | — |
| Nov 14, 2023 | AMC | — | -4.20 | — | 5.60 | +0.0% | +0.0% | -3.6% | -3.7% | +0.0% | +3.8% | — |
| Nov 13, 2023 | TNS | — | -4.20 | — | 5.80 | -3.4% | -3.4% | +0.0% | -3.6% | -3.7% | +0.0% | — |
| Sep 27, 2023 | AMC | -0.41 | 0.26 | +163.4% | 5.80 | +0.0% | +0.0% | +3.4% | +3.3% | -3.2% | -6.7% | — |
| May 11, 2023 | AMC | -3.42 | -6.61 | -93.4% | 20.20 | +0.0% | +0.0% | -6.9% | -1.1% | +3.2% | -1.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 17 | H.C. Wainwright | Initiates | Buy | $7 | $1.18 | $1.25 | +5.9% | +5.9% | +2.4% | -1.6% | +5.6% | -6.4% |
| Jun 8 | Raymond James | Initiates | Outperform | $5 | $1.82 | $1.87 | +2.7% | -4.9% | -1.7% | +0.0% | -1.8% | +1.2% |
| Jun 5 | B. Riley Securities | Initiates | Buy | $6 | $1.93 | $1.93 | +0.0% | -5.7% | -4.9% | -1.7% | +0.0% | -1.8% |
| Apr 9 | Chardan Capital | Maintains | Buy → Buy | — | $2.24 | $2.23 | -0.4% | -1.8% | -1.8% | +1.9% | -0.5% | -4.1% |
| Mar 18 | Chardan Capital | Maintains | Buy → Buy | — | $2.46 | $2.49 | +1.2% | -11.0% | -4.1% | -0.5% | +5.7% | -5.9% |
| Feb 12 | Chardan Capital | Maintains | Buy → Buy | — | $2.21 | $2.20 | -0.5% | -4.5% | +5.2% | +3.2% | +1.7% | +5.2% |
| Jun 25 | Chardan Capital | Maintains | Buy → Buy | — | $0.75 | $0.73 | -2.7% | -2.7% | -2.7% | +6.3% | +1.1% | -1.7% |
| May 6 | Chardan Capital | Maintains | Buy → Buy | — | $0.98 | $0.98 | +0.0% | -13.3% | +0.0% | -2.4% | -7.2% | +2.6% |
| May 5 | Chardan Capital | Maintains | Buy → Buy | — | $1.01 | $1.09 | +7.9% | -3.0% | -13.3% | +0.0% | -2.4% | -7.2% |
| Jun 3 | Chardan Capital | Maintains | Buy → Buy | — | $2.38 | $2.45 | +2.9% | +1.3% | +4.6% | -2.0% | -1.2% | -0.8% |
| Oct 7 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $80.00 | $80.00 | +0.0% | -12.5% | -13.1% | -18.8% | -1.6% | -2.9% |
| Nov 29 | JMP Securities | Maintains | Outperform → Outperform | — | $330.00 | $360.00 | +9.1% | +28.8% | -11.8% | +1.3% | -3.9% | -9.6% |
| Jan 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $730.00 | $885.00 | +21.2% | +20.5% | -2.8% | +0.6% | -2.9% | -4.8% |
| Jan 21 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $725.00 | $735.00 | +1.4% | +0.7% | +20.5% | -2.8% | +0.6% | -2.9% |
| Jun 26 | Alliance Global Partners | Maintains | Buy → Buy | — | $805.00 | $1260.00 | +56.5% | +33.5% | +14.4% | -9.8% | -6.3% | -5.8% |
No insider trades available.
8-K · 8.01
!! High
iBio, Inc. -- 8-K 8.01: Material Event / Announcement
Sep 14
8-K · 2.02
!! High
iBio, Inc. -- 8-K 2.02: Earnings Results
Aug 28
8-K · 8.01
!! High
iBio, Inc. -- 8-K 8.01: Material Event / Announcement
Aug 4
8-K · 8.01
!! High
iBio, Inc. -- 8-K 8.01: Material Event / Announcement
Jul 17
8-K · 8.01
!! High
iBio, Inc. -- 8-K 8.01: Material Event / Announcement
Jul 1
8-K · 5.02
!!! Very High
iBio, Inc. -- 8-K 5.02: Executive Change
May 8
8-K · 8.01
!! High
iBio, Inc. -- 8-K 8.01: Material Event / Announcement
iBio corrected the expiration date of Series G warrants covering 35.77 million common shares, fixing a typographical error in its original 8-K filing.
Apr 17
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
iBio cleared regulatory hurdles to start Phase 1 trials of IBIO-600 in Australia, potentially validating its clinical pipeline and de-risking development, though human efficacy data remains years away.
Apr 8
8-K · 8.01
!! High
iBio, Inc. -- 8-K 8.01: Material Event / Announcement
iBio released preclinical data showing IBIO-610, a potential first-in-class Activin E antibody, improved body composition in obese non-human primates, advancing its obesity treatment pipeline.
Mar 9
8-K · 1.02
!! High
iBio, Inc. -- 8-K 1.02: Material Agreement Terminated
iBio terminated its at-the-market offering agreement with Jefferies, eliminating a source of potential future capital raises and reducing the company's financing flexibility.
Feb 27
8-K
iBio, Inc. -- 8-K Filing
iBio secured $26 million in PIPE financing from a top-tier biotech investor to extend cash runway and advance its preclinical pipeline programs.
Feb 10
Institutional (13F) — Top 0
All ↗
No 13F holders found.
Mutual Funds / ETFs (N-PORT) — Top 1
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Guggenheim Active Allocation Fund | 2 | $6 | Feb 2026 |
Valuation
Market Cap
$18.8M
Enterprise Value
$4.0M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.01x
P/B
0.84x
P/S
124.94x
P/FCF
-0.82x
EV/EBITDA
—
Shares Out
10.5M
Financials (TTM)
Revenue
$100K
Net Income
-$33.0M
EBITDA
-$32.3M
Free Cash Flow
-$15.3M
Op Cash Flow
-$15.3M
EPS Basic
$-1.75
EPS Diluted
$-0.33
EPS Forward
$-0.31
Gross Margin
100.0%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$23.2M
Total Liab.
$8.3M
Total Equity
$14.9M
Cash
$8.6M
LT Debt
$0
Book Value/Sh
$1.42
Debt/Equity
0.24x
Current Ratio
1.59
Quick Ratio
1.59
Returns & Growth
ROE
-40.7%
ROA
-35.7%
ROIC
-101.2%
Rev Growth YoY
+77.8%
EPS Growth YoY
+73.1%
Price Returns
2W
-2.4%
1M
-18.4%
3M
-24.5%
6M
-45.0%
12M
+50.6%
Technicals
52W High
$3.82
52W Low
$0.78
50d MA
$1.36
200d MA
$1.85
RSI (14)
39.10
ATR (14)
$0.06
Beta
1.36
Avg Volume
737K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$2.80
High
$3.60
Low
$2.00
Median
$2.80
Data updated apr 25, 2026 2:44pm
· Source: financialmodelingprep.com